UBS Sticks to Their Buy Rating for QBE Insurance Group Limited (QBEIF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chidgey covers the Financial sector, focusing on stocks such as ASX , Insurance Australia Group Limited, and QBE Insurance Group Limited. According to TipRanks, Chidgey has an average return of 9.9% and a 58.33% success rate on recommended stocks.
In addition to UBS, QBE Insurance Group Limited also received a Buy from TR | OpenAI – 4o's Wesley Roofguard in a report issued on July 16. However, on July 2, Macquarie downgraded QBE Insurance Group Limited (Other OTC: QBEIF) to a Hold.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UBS Trims Colgate (CL) Price Target, Maintains Buy Rating
Colgate-Palmolive Company (NYSE:CL) is one of the most profitable consumer stocks to buy now. UBS lowered its price target on Colgate-Palmolive (NYSE: CL) to $106 from $109 while maintaining a Buy rating, citing valuation discipline following the stock's steady run in recent months. At the current price of $86.80, the revised target still implies an upside potential of roughly 22%. An array of toothpaste, toothbrushes, and mouthwashes on a bright background, highlighting the company's oral care products. The firm continues to see strength in Colgate's underlying fundamentals, particularly its strong pricing execution across global markets and steady demand for essential personal care and household products. UBS analysts noted that while foreign exchange and cost headwinds remain part of the equation, margin recovery efforts and disciplined brand investments are likely to support earnings growth through the back half of the year. Colgate has seen consistent performance across its oral care and pet nutrition segments, with emerging markets showing signs of improving volumes. The updated target reflects a more balanced outlook as shares approach levels UBS considers closer to fair value, rather than a change in conviction about the company's prospects. Investors will be watching Colgate's next earnings update for clarity on input cost trends and competitive dynamics, particularly as pricing begins to normalize and volume growth comes back into focus. While we acknowledge the potential of CL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
UBS Raises Monster (MNST) Price Target, Maintains Neutral Rating
Monster Beverage Corporation (NASDAQ:MNST) is one of the most profitable consumer stocks to buy now. UBS raised its price target on Monster Beverage Corporation. (NASDAQ:MNST) to $64 from $63 on July 17, maintaining a Neutral rating as the firm continues to take a measured view of the energy drink giant's near-term prospects. The modest adjustment reflects incremental optimism around the company's distribution gains and innovation pipeline, but also suggests limited room for outperformance at current levels. Monster, which has faced intensified competition from new entrants and legacy beverage rivals alike, has been leaning on international expansion and product extensions to maintain momentum. UBS analysts noted that while those initiatives are showing progress, the overall U.S. market has grown more crowded, putting pressure on shelf space and pricing. The company's recent launch of alcoholic offerings under The Beast Unleashed brand has drawn interest, but UBS appears to be waiting for more evidence of meaningful revenue contribution before revising its broader outlook. Monster shares have traded in a relatively tight range over the past quarter, as investors weigh category growth against margin pressures from higher input costs. With the stock hovering below 8.5% of the new target, the neutral call underscores a wait-and-see approach from UBS as the company navigates a shifting competitive landscape. While we acknowledge the potential of MNST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
UBS Trims P&G (PG) Price Target, Maintains Buy Rating
The Procter & Gamble Company (NYSE:PG) is one of the most profitable consumer stocks to buy now. UBS analyst Peter Grom lowered his price target on The Procter & Gamble Company (NYSE:PG) to $180 from $186 while maintaining a Buy rating, citing refined estimates ahead of the company's fiscal fourth-quarter results. Despite the downward adjustment, the revised target still implies an upside of about 16% from the current price of $155. Copyright: jetcityimage / 123RF Stock Photo The move reflects a more tempered near-term view rather than a shift in long-term confidence. UBS continues to see strength in P&G's brand portfolio, which spans core categories like fabric care, grooming, and personal health. Grom noted that while foreign exchange pressures and consumer trade-down behavior are worth watching, the company's pricing power and cost discipline remain key pillars of its strategy. P&G has held up well in a mixed consumer environment, benefiting from its exposure to everyday essentials and global scale. The company's ability to maintain share across several categories, even amid softer volumes, has kept investor sentiment generally positive. As earnings season approaches, analysts will be looking for commentary on volume recovery and input costs, particularly as inflation eases in certain regions. The new target reflects modest caution without undermining the firm's broader bullish stance on P&G's market positioning. While we acknowledge the potential of PG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade Disclosure: None.
